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INTRODUCTION
Liver transplantation (LTx) has become recognized
as a standard treatment for end-stage liver disease.
However, despite an increase in potential transplant
patients, a serious shortage of donor organs has limited
its clinical application. The use of non-heart-beating
donors (NHBDs) could relieve the donor organ short-
age provided that the outcome of the recipient is not
jeopardized. Furthermore, recent estimates indicate
that an increase of 20-25% in organ donors could be
realized if NHBDs were used routinely (1). In NHBDs,
the liver inevitably suffers from warm ischemia injury
related cardiac arrest before cold perfusion. Thus, new
modalities to attenuate these ischemia reperfusion
injuries are required to establish the safety and effi-
cacy of LTx from NHBDs.
FK506, a powerful immunosuppressive agent, may
enhance hepatocyte regeneration, andmay also ame-
liorate hepatic ischemia-reperfusion injury of the liver.
The effect is great interest and is worthy of thorough
investigation, because the augmentation of hepatic re-
generation and protection from ischemic injury may
be crucial not only in liver transplantation, but also
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in other types of liver surgery.
Ischemia-reperfusion injury is a complex series of
multistep processes. It has been shown that ischemia
can activate phospholipase A2, with the consequent
release of free arachidonic acid from the cell mem-
branes.
Thromboxane A2 (TXA), themain product of arachi-
donic acidmetabolism in platelets, works as a powerful
platelet aggregating agent and a stimulator of contractive
activity of smoothmuscles including the blood vessels
and trachea. Accordingly, TXA can exacerbate the pro-
gression of ischemia-induced liver damage (2). OKY046
(sodium(E)-3-[4-(1)-imidazolylmethl phenyl]) is a spe-
cific thromboxane synthetase inhibitor which sup-
presses the production of TXAwithout affecting other
cyclooxygenase pathways. Several reports have sug-
gested thebeneficialeffectof thisdrugonwarmischemic
damage to the liver after reperfusion and on cold pres-
ervation/reperfusion injury of the liver (3).
In the present study, to investigate the possibility
of pharmacologic modulation of the hepatic allograft
function from NHBDs, the effects of treatment with
FK506 and OKY046 were evaluated in rat orthotopic
liver transplantation.
MATERIALS AND METHODS
Animals
Male Lewis rats 8 to 9 weeksweighing 190 to 250 g
supplied from Charles River Japan (Yokohama, Japan)
were used for both donors and recipients. The ratswere
selected because they have no rejection each other.
All rats were allowed free access towater and standard
laboratory diet until just before operation.
Liver transplantation
Room temperature during liver transplantation was
maintained around 23℃. The induction of general
anesthesia was Ether inhalation. Five minutes after
administration of 5000 IU intravenous heparin in do-
nors, the abdominal aorta were cut and cardiac arrest
was induced by phlebotomy as a model from NHBDs.
Then, warm ischemiawas induced for 60min at room
temperature. At the end of the warm ischemia period,
the graft was perfused in situ via the portal vein with
10 ml of chilled lactated Ringer’s solution. The liver was
harvested and stored cold in a bath of the same solution
until transplantation. The graft from the NHBDs was
transplanted orthotopically by the technique described
by Kamada and Calne (4) with minor modifications.
The suprahepatic vena cava was anastomosed with
6-0 Prolene (Ethicon, Somerville, NJ) continuous su-
ture and portal vein, and infrahepatic vena cava recon-
struction was performed by the cuff technique. The bile
duct connection was made with the use of an intralu-
minal splint. A 16G intravenous catheter (TERUMO,
Tokyo, Japan) was used for the portal vein cuff and in-
frahepatic vena cava. And a 22G intravenous catheter
was used for the cuff of the bile duct splint. No attempt
was made to anastomose the hepatic artery. After clos-
ing the abdomen, the recipients were warmed with
a heating lamp for 30 min. All of the recipients for the
survival study were transferred to an individual cage
after LTx in a room in which the temperature was con-
stantly maintained at 23℃ and observed daily for two
weeks. Food pellet andwaterwere available at all times.
The recipients for sample collectionwere killed 30min,
60 min and 180 min after reperfusion. Immunosup-
pressants were not administrated during or after the
operation.
The donor groups
The donors were divided into 4 groups before liver
transplantation. Group 1, (Control group) ; The rats in
Group 1 were treated with vehicle. Group 2, (FK506
group) ; The rats in Group 2 were treatedwith FK506
(Fujisawa Pharmaceuticals Ltd., Osaka Japan) 1.0mg/
kg/day intramuscularly for 4 days just prior to warm
ischemia. Group 3, (OKY046 group) ; The rats inGroup
3 were treated with OKY046 (Ono Pharmaceutical,
Osaka Japan) 10 mg/kg intravenously through the
penile vein for 60 min, 40 min, 20 min before the in-
duction of warm ischemia. Then, the total volume of
OKY046 was 30 mg/kg. Group 4, (FK506＋OKY046
group) ; The rats in Group 4 were treated both with
FK506 and OKY046 by the same methods. The dose
of FK 506 and OKY 046 were determined following
the protocol of previous authors (1, 21). The recipients
received transplantations from a rat in one of these
donor groups using the previously described technique.
Blood chemical analysis
Blood samples were drawn from the abdominal
aorta, and the samples were centrifuged immediately
at 3000 rpm, at 4℃ for 5 min for the determination of
serum Aspartate aminotransferase (AST), Alanine
aminotransferase (ALT) and Lactate dehydrogenase
(LDH), which were measured using an autoanalyzer.
The remaining plasmawas stored in a freezer and used
for measuring Interleukin 6(IL-6) and tumor necrosis
factor-α(TNF-α), which are inflammatory cytokines.
An ELISA kit (TFB, Tokyo, Japan) was used to perform
measurements of IL-6 and TNF-α.
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Histological examinations
For light microscopy, liver tissue were taken at 30
min, 1 hr, and 3 hr after reperfusion, and they were
fixed in 4% formaldehyde, processed routinely, and
embedded in paraffin. Thick paraffin sections were
stained with hematoxylin and eosin.
Statistical analysis
The results were expressed as mean±SD. Differ-
ences in survival were determined using the Kaplan-
Meier Survival Analysis. All laboratory data, including
AST, ALT, LDH, IL-6, TNF-α relationship withGroups
were tested by the repeated measures ANOVA, and
the differences of effects between the groups were
tested by post hoc test (Fisher’s PLSD analysis). All
statistical analysis was performed using the computer
software package Statview V (Abacus Concepts, Ber-
keley, California). P< 0.05 was considered significant.
RESULTS
There was no significant difference in anhepatic
time, cold ischemic time and recipient’s operation time
time (Table 1).
Postoperative survival
In the recipients, postoperative survival was assessed
for 14 days (Fig. 1). All of the rats inGroup 4 (n=6) sur-
vived (6/6, 100%). In Group 2 (n=6) andGroup 3 (n=6),
5 out of the 6 rats survived (5/6, 83%). InGroup 1, only
2 out of the 6 rats survived for 14 days, and there was
a significant difference between Group 1 and Group 4
(P <0.05). In Group 1, the deaths of the 4 rats all oc-
curred within 2 days, and the remaining 2 rats sur-
vived for 14 days. In Group 2 and Group 3, the deaths
also occurred within 2 days. The cause of all these
deaths was hepatic failure because they had no bleed-
ing and no intra-operative or post-operative complica-
tions. It was suggested that life-threatening microcir-
culation disorders occurred a relatively short time after
reperfusion. It was also assumed that a concomitant
administration of FK505 and OKY046 had a stronger
protective effect than an administration of either FK
506 or OKY 046.
Serum liver enzymes and inflammatory cytokine
The serum AST concentrationwas higher inGroup 1
than in the drug-treated Groups (Fig. 2). There was
alternans action between the serumAST concentration
and Groups (F=2.367, p<0.05). InGroup 1, the AST con-
centrations were high immediately after reperfusion.
Table 1. Operation times between four groups
For each group, anhepatic time, cold ischemia time and operation
time are shown. There was no significant difference between the
4 groups.
Time(min) (mean±S.D.)
Group Anhepatic Cold ischemic Recipient operation time
Group 1
Control
(n=27)
12.8±0.9 35.4±3.1 38.8±1.9
Group 2
FK506
(n=24)
12.7±0.7 35.6±2.9 39.0±2.4
Group 3
OKY
(n=27)
12.3±0.6 34.8±2.7 37.0±2.2
Group 4
FK＋OKY
(n=24)
12.5±0.9 35.2±3.2 38.4±2.2
Figure. 1. 14 days survival
The 14-day survival rate of each group is shown. All the deaths
occurred within 2 days of the transplantations. There was a
significant difference between Group 1 and Group 4.
Figure. 2. Serum AST concentrations after reperfusion
Immediately after reperfusion, the serum AST concentrations in
Group 2, Group 3 and Group 4 were lower than in Group 1. 360 min
after reperfusion, there were statistically significant differences
when Group 1 was compared to Group 2, Group 3 and Group 4.
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At 360 min after reperfusion, the AST concentration
in Group 1 (12058.6±6108.2 IU/L) was significantly
higher than in Group 2 (4620.0±1597.7 IU/L,P<0.01),
in Group 3 (5268.3±3114.4 IU/L, P<0.01) andGroup 4
(3016.7±1487.2 IU/L, P<0.01). Especially, the AST
concentrations were particularly low inGroup 4. The
serum ALT concentrations in the drug-treated groups
were lower than in the control group after reperfusion.
There was alternans action between the serum ALT
concentration and Groups (F=2.727, p<0.05). And at 60
min after reperfusion, the serumALT concentration was
significantly lower in Group 4 (1676.7±133.2 IU/L)
than in Group 2 (3600.0±959.0 IU/L, P <0.05) and
Group 3 (2025±289.9 IU/L, P<0.05). At 360 min after
reperfusion, the serumALT concentrationwas signifi-
cantly higher in Group 1 (8672.9±4373.3 IU/L) than
in Group 2 (3615.0±1662.7 IU/L, P<0.01), Group 3
(2886.7±1094.3 IU/L, P<0.01) and Group 4 (2511.7±
1614.9, P <0.01)(Fig. 3). The serum LDH at 360 min
after reperfusion in Group 1 (80814.3±40370.9 IU/L)
was also higher than in the drug-treatedGroups {Group
2 (29923.3±25702.5 IU/L) (P<0.01), Group 3 (18681.7±
13495.4 IU/L) (P<0.01), Group 4 (15401.7±21211.3
IU/L) (P<0.01)}. There was alternans action between
the serum LDH concentration and Groups (F=3.264,
p<0.05). And at 60 min after reperfusion, the serum
LDH concentration was significantly lower inGroup 4
(20176.7±3067.2 IU/L) than in Group 2 (43100.0±
13046.1 IU/L, P<0.05) and Group 3 (26485.0±700.0
IU/L, P<0.05)(Fig. 4). The serum concentrations of in-
terleukin 6 (IL-6), which is an inflammatory cytokine,
were considerably higher in the control group than
in the drug-treated groups immediately after reper-
fusion. There was alternans action between the serum
Figure. 3. Serum ALT concentration after reperfusion
Immediately after reperfusion, the serum ALT concentrations
were lower in Group 3 and Group 4 than in Group 1. 360 min
after reperfusion, there were statistically significant differences
when Group 1 was compared to Group 2, Group 3 and Group 4.
Figure. 4. Serum LDH concentrations after reperfusion
360 min after reperfusion, there were statistically significant differ-
ences in the serumLDHconcentrationswhenGroup1was compared
to Group 2, Group 3 and Group 4.
Figure. 5. Serum IL-6 concentrations after reperfusion
Immediately after reperfusion, the serum IL-6 concentrations were
considerably higher in Group 1 than in Group 2, Group 3 and
Group 4. 360min after reperfusion, there were statistically significant
differences when Group 1 was compared to Group 2, Group 3 and
Group 4.
Figure. 6. Serum TNF-α concentrations after reperfusion
The high serum TNF-α concentrations in Group 1 persisted until
360 min after perfusion. In Group 2, Group 3 and Group 4, these
concentrations gradually decreased. 360 min after reperfusion,
there were statistically significant differences when Group 1 was
compared to Group 2, Group 3 and Group 4.
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IL-6 concentration and Groups (F=4.381, p<0.01). And
the differences between them 360 min after reperfu-
sion was statistically significant (Group 1 : 757.4±
256.1 pg/ml) (Group 2:313.2±117.5 pg/ml, P<0.01)
(Group 3 : 278.0±102.2 pg/ml, P <0.01)(Group 4 :
282.0±121.1 pg/ml, P<0.01)(Fig. 5). InGroup 1, high
concentrations of TNF-αwere observed immediately
after reperfusion and persisted until 360 min after
perfusion. In the drug-treated groups, although high
concentrations of TNF-αwere also observed immedi-
ately after reperfusion, they gradually decreased and,
360 min after reperfusion, were significantly lower
than in Group 1 (Group 1 : 179.6±100.6 pg/ml) (Group
2 : 59.8±22.7 pg/ml, P <0.05)(Group 3 : 55.1±11.1
pg/ml, P<0.05)(Group4 :57.4±3.6 pg/ml, P<0.05).
But there was no alternans action between the serum
TNF-α concentration and Groups (F=0.670, p=0.674)
(Fig. 6).
Histological findings
At 360 min after reperfusion, light microscope find-
ings revealed that, in Group 1, erythrocytes were fre-
quently sludged in the sinusoids, and the hepatocyte
vacuolization was prominent, as shown in Fig. 7a. By
contrast, in the drug-treated groups, only isolatederyth-
rocytes were found, and the hepatocyte vacuolization
was minimal (Fig. 7 b, c, d).
At 360 min after reperfusion, there was no signifi-
cant difference in the laboratory data and the survival
rates, and there was no difference in the histological
findings between the group inwhich the 2 drugs were
concomitantly used (Group 4) and the groups in which
each drug was used separately (Group 2 and Group
3). However, all the parameters were better in Group
4 than in Group 2 and Group 3, and there was a sig-
nificant difference of survival rate between only in
Group 1 and Group 4.
DISCUSSION
Liver transplantation (LTx) has emerged as highly
successful therapy for patients with liver failure. The
A : Group 1 B : Group 2
C : Group 3 D : Group 4
Figure. 7. Histological findings
A) Erythrocytes were frequently sludged in the sinusoids, and the hepatocyte vacuolization was prominent.
B, C, D) Only isolated erythrocytes were found, and the hepatocyte vacuolization was minimal.
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critical shortage of transplantable organs has man-
dated the pursuit of safe transplantation using uncon-
ventional donor organs (5). Over the past few years,
NHBDs have composed approximately 1 % of the total
cadaveric donors, but there are estimates that con-
trolled NHBDs have the potential to increase the ca-
daver donor pool by 25-42%, with at least 1,000 con-
trolled NHBDs each year (6, 7). Transplantation of
organs from NHBDs could help to decrease the dis-
parity in organ supply and demand. Themain obstacle
to the use of livers from NHBDs is warm ischemia to
the liver related to cardiac arrest. Liver grafts from
NHBDs are unsuitable for LTx because the graft viabil-
ity is deteriorated bywarm ischemia and severe reper-
fusion injury. Clinical and experimental reports sug-
gest that the liver can tolerate warm ischemia, even
for periods up to 60min andmore (8). However, in LTx,
the allograft sustains inevitable cold ischemia in addition
to re-warming injury during vascular anastomoses. To
increase the number of viable hepatic allografts avail-
able from NHBDs, new strategies are required.
Recent studies have demonstrated that FK506, in
addition to being a powerful immunosuppressive agent,
ameliorates the hepatic injury induced by normother-
mic ischemia and reperfusion (9). There is evidence
that FK506 enhances, in the early phase of reperfusion,
adenosine triphosphate (ATP) recovery and diminishes
peroxidative damage in ischemically injured hepato-
cytes (10). FK506 has also been shown, in the later
phase of the reperfusion period, to inhibit TNF-α, which
may activate endothelial cells to express adhesionmole-
cules and to secrete platelet-activating factor (PAF)
(11). Thus, the beneficial effect of this immunosup-
pressant on hepatic ischemia is multifactorial (9).
On the other hand, TXA is a prostaglandin, which
potently induces platelet aggregation and vascular con-
traction (12). This factor is increased by the ischemic
injury of organs, host rejection of transplanted organs,
trauma, and shock (13, 14). Thus, anti-TXA agents are
reported to reduce ischemia-induced organ injury
and the degree of rejection (12). OKY046 is a specific
thromboxane synthetase inhibitor, which suppresses
the production of TXAwithout affecting other cyclooxy-
genase pathways. Several reports have suggested the
beneficial effect of this drug on warm ischemic dam-
age to the liver after reperfusion and on cold preser-
vation/reperfusion injury of the liver (3).
Consequently, FK506 and OKY046 have a com-
pletely different mechanism of preventing ischemia/
reperfusion injury. Concomitant use of these 2 drugs
may make LTx fromNHBDs safer. In this study, the
survival rate in the FK506＋OKY046 groupwas signifi-
cantly higher than in the control group. Until 6 hr after
reperfusion, the serum ALT, AST and LDH concen-
trations increased in the control group, while in the
FK506 group, the OKY046 group and the FK506＋
OKY046 group, these levels peaked 3 hr after reper-
fusion and thereafter significantly decreased. Especially
in the FK506＋OKY046 group, these concentrations
decreased the most. In the control group, the concen-
trations of TNF-α significantly increased 60min after
reperfusion and remained high until 6 hr after perfu-
sion. However, 6 hr after reperfusion, this concentration
was significantly lower in the other 3 groups than in
the control group, and in the FK506＋OKY046 group,
this level was also significantly lower than in the control
group after 3 hr of reperfusion. Until 6 hr after reperfu-
sion, the IL-6 concentration in the control group in-
creased, while this concentration remained low in
the other 3 groups. This concentration was low 3 hr
after reperfusion only in the FK506＋OKY046 group.
TNF-α is clearly an important mediator of ischemia/
reperfusion injury (15). Specifically, TNF-α has been
documented to activate neutrophils to produce local
damage during hepatic ischemia/reperfusion injury
(16). In addition, the release of TNF-α after injury not
only mediates local injury, but participates in distant
organ dysfunction as well (17). Also, undefinedmecha-
nisms of tissue toxicity by TNF-α exist that are not
coupled with neutrophil activity (18). Neutralization
of TNF-α has been documented to decrease hepatocel-
lular damage after ischemia/reperfusion injury (18).
Investigation of hepatic ischemia has shown that FK
506 pretreatment reduces TNF-α levels, as well as neu-
trophil migration (19). Other studies have shown that
FK506 pretreatment results in decreased expression
of IL-6 (20).
The donor pretreatment with OKY046 reduces in-
trahepatic thromboxane production after reperfusion,
and pretreatment of NHBDs with OKY046 reduces
liver endothelial cell damage and injury to the micro-
circulation after reperfusion (1). In this study, TNF-α
and IL-6 were inhibited by the administration of OKY
046 alone, as well as by the administration of FK506.
The cause of this is assumed to be that the platelet
aggregation inhibiting effect of OKY046 reduced the
cellular damage, and the secondary release of inflam-
matory cytokines, which was induced by the cellular
damage, was inhibited (Fig. 8). By concomitantly using
these 2 drugs, additive effects are expected during LTx
from NHBDs. However, regarding pretreatment of
donors, further evaluation is required, including the
side effects of drugs.
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CONCLUSION
In conclusion, we demonstrated that pretreatment
of NHBDs with pharmacologic modulation of FK
506 and OKY046 ameliorated graft viability.
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